Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Carcinoma, Hepatocellular 2Triple Negative Breast Neoplasms 1Pancreatic Neoplasms 1Nasopharyngeal Carcinoma 1Carcinoma, Non-Small-Cell Lung 1Breast Neoplasms 1

Interventions

pembrolizumab 67Carboplatin 67Pemetrexed 58Cisplatin 44Paclitaxel 26Nivolumab 26Specimen Handling 25durvalumab 24osimertinib 21Docetaxel 21Magnetic Resonance Spectroscopy 20Gemcitabine 17amivantamab 14Cetuximab 14130-nm albumin-bound paclitaxel 13atezolizumab 12lazertinib 11Radiosurgery 10Radiotherapy 9Ipilimumab 9Bevacizumab 9Taxes 8cemiplimab 7Ramucirumab 7Drug Therapy 7alectinib 6Observation 6Radiation 5Leucovorin 5Immunoglobulin G 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Carcinoma, Non-Small-Cell Lung × camrelizumab × 30 days × Clear all
NCT04768075 2026-05-20

Camrelizumab Combined With SRT/WBRT and Chemotherapy in Patients With Brain Metastases of Driven Gene-negative NSCLC

Guangdong Association of Clinical Trials

Phase 3 Completed
60 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung

Data powered by HemOnc (CC BY 4.0) Colophon âš¡